ADVERTISEMENT
What the Alzheimer’s Drug Breakthrough Means for Other Diseases
The CEO of Japanese pharma company Eisai says the medication’s success can advance treatments for conditions with similar causes.
27 Oct 2022, 10:36 AM IST
(Bloomberg Businessweek) -- It’s been three decades since scientists hypothesized that Alzheimer’s is caused by a buildup of amyloid beta protein in the brain. But it wasn’t until last month that drugmakers achieved a major breakthrough, with Japan’s Eisai Co. and its US partner Biogen Inc. releasing results from a large-scale trial showing they were able to blunt the disease’s progression. The companies are seeking accelerated US ...
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Members-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories
20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Members-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT